Details for Patent: RE47691

« Back to Dashboard

Which drugs does patent RE47691 protect, and when does it expire?

Patent RE47691 protects VYONDYS 53 and is included in one NDA.

This patent has thirty patent family members in thirteen countries.

Summary for Patent: RE47691

Title:	Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Abstract:	An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
Inventor(s):	Stephen Donald Wilton, Sue Fletcher, Graham McClorey
Assignee:	University of Western Australia
Application Number:	US15/645,842
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE47691
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent RE47691

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019		RX	Yes	Yes			Y

International Family Members for US Patent RE47691

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E498685
Cyprus	1111447
Cyprus	1117475
Germany	602005026386
Denmark	1766010
Denmark	2206781